

# Armando Tripodi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7948115/armando-tripodi-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189  
papers

9,616  
citations

47  
h-index

95  
g-index

198  
ext. papers

11,146  
ext. citations

6.2  
avg, IF

6.74  
L-index

#	Paper	IF	Citations
189	Antithrombotic Therapy and Liver Disease <b>2022</b> , 249-265		
188	Cirrhosis. What are all those factor VIII and protein C for?. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	
187	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.. <i>Vascular Pharmacology</i> , <b>2022</b> , 106994	5.9	
186	Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban.. <i>International Journal of Laboratory Hematology</i> , <b>2022</b> ,	2.5	
185	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> ,	15.4	3
184	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISST). <i>Blood Transfusion</i> , <b>2021</b> , 19, 14-23	3.6	3
183	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e1660-e1672	5.6	0
182	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1116-1122	15.4	18
181	Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1372-1378	15.4	6
180	Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2021</b> , 59, 1699-1708	5.9	0
179	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ�Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ�Italiana per lo Studio dell'Emostasi e della Trombosi (SISST). <i>Journal of Nephrology</i> , <b>2021</b> , 34, 31-38	4.8	3
178	Hemostatic alterations in COVID-19. <i>Haematologica</i> , <b>2021</b> , 106, 1472-1475	6.6	24
177	Relationship between thrombin generation parameters and prothrombin fragment 1+2 plasma levels. <i>International Journal of Laboratory Hematology</i> , <b>2021</b> , 43, e248-e251	2.5	1
176	Anti-TNF-� Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1901-1908	4.5	2
175	Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. <i>Haematologica</i> , <b>2021</b> , 106, 3021-3024	6.6	4
174	Diagnostic Challenges on the Laboratory Detection of Lupus Anticoagulant. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
173	Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. <i>Thrombosis Research</i> , <b>2021</b> , 204, 32-39	8.2	2

172	No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2. <i>Thrombosis Update</i> , <b>2021</b> , 4, 100059	0.9	1
171	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 3117-3118	15.4	1
170	Letter to the Editor: Thromboelastography-Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?. <i>Hepatology</i> , <b>2020</b> , 72, 1158-1159	11.2	0
169	Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study. <i>International Journal of Laboratory Hematology</i> , <b>2020</b> , 42, e128-e131	2.5	1
168	Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 519-525	3.8	5
167	Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. <i>Thrombosis Research</i> , <b>2020</b> , 190, 20-25	8.2	3
166	Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 59, 365-371	5.9	4
165	Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial". <i>Blood Transfusion</i> , <b>2020</b> , 18, 239-240	3.6	1
164	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. <i>Blood Transfusion</i> , <b>2020</b> , 18, 478-485	3.6	168
163	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , <b>2020</b> , 18, 167-169	3.6	168
162	Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. <i>Thrombosis Research</i> , <b>2020</b> , 185, 96-101	8.2	5
161	Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 413-419	5.1	2
160	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. <i>Haemophilia</i> , <b>2020</b> , 26, 937-945	3.3	10
159	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2828-2839	15.4	57
158	Usefulness of Thrombin Generation. <i>Hamostaseologie</i> , <b>2020</b> , 40, 509-514	1.9	1
157	Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. <i>Frontiers in Pediatrics</i> , <b>2020</b> , 8, 510	3.4	1
156	Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 85-94	13.4	39
155	Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth?. <i>Transfusion</i> , <b>2020</b> , 60, 1069-1077	2.9	4

154	Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1569-1575	15.4	38
153	Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1738-1742	15.4	787
152	Thromboelastographic profiles of healthy very low birthweight infants serially during their first month. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , <b>2020</b> , 105, 412-418	4.7	11
151	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 52-60	5.1	5
150	Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. <i>Gastroenterology</i> , <b>2019</b> , 156, 1582-1599.e1	13.3	121
149	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. <i>Vascular Pharmacology</i> , <b>2019</b> , 113, 92-93	5.9	2
148	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. <i>Liver International</i> , <b>2019</b> , 39, 2309-2316	7.9	5
147	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. <i>Thrombosis Research</i> , <b>2019</b> , 174, 84-87	8.2	4
146	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. <i>Clinical Chemistry</i> , <b>2019</b> , 65, 254-262	5.5	17
145	Response to Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy. <i>Liver International</i> , <b>2018</b> , 38, 186	7.9	
144	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 1029-1036	3.7	17
143	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. <i>Haematologica</i> , <b>2018</b> , 103, e315-e317	6.6	18
142	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1146-1152.e4	6.9	46
141	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the Siset, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , <b>2018</b> , 16, 462-470	3.6	35
140	The intra-assay reproducibility of thromboelastography in very low birth weight infants. <i>Early Human Development</i> , <b>2018</b> , 127, 48-52	2.2	9
139	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. <i>Liver International</i> , <b>2017</b> , 37, 1295-1303	7.9	14
138	Hemostasis in Acute and Chronic Liver Disease. <i>Seminars in Liver Disease</i> , <b>2017</b> , 37, 28-32	7.3	22
137	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 1109-1119	3.7	25

136	Critical laboratory values in hemostasis: toward consensus. <i>Annals of Medicine</i> , <b>2017</b> , 49, 455-461	1.5	12
135	Commentary. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 1445-1446	5.5	
134	Lupus Anticoagulant Testing: Activated Partial Thromboplastin Time (APTT) and Silica Clotting Time (SCT). <i>Methods in Molecular Biology</i> , <b>2017</b> , 1646, 177-183	1.4	5
133	Changing Concepts of Cirrhotic Coagulopathy. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 274-281	10.7	110
132	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 248-250	13.4	14
131	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. <i>Endocrine</i> , <b>2017</b> , 56, 298-307	4	19
130	Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 830-836	7	25
129	Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. <i>Liver International</i> , <b>2016</b> , 36, 1322-30	7.9	36
128	How to report results of prothrombin and activated partial thromboplastin times. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, 215-22	5.9	14
127	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. <i>International Journal of Hematology</i> , <b>2016</b> , 103, 165-72	2.3	11
126	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. <i>Thrombosis Research</i> , <b>2016</b> , 137, 178-183	8.2	105
125	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 455-467	3.3	41
124	Thrombin Generation Assay and Its Application in the Clinical Laboratory. <i>Clinical Chemistry</i> , <b>2016</b> , 62, 699-707	5.5	164
123	Extracellular vesicle-driven information mediates the long-term effects of particulate matter exposure on coagulation and inflammation pathways. <i>Toxicology Letters</i> , <b>2016</b> , 259, 143-150	4.4	28
122	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1208-13	3.3	18
121	Periprocedural management of rivaroxaban-treated patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 685-91	4	4
120	Liver Disease and Hemostatic (Dys)function. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2015</b> , 41, 462-7	5.3	35
119	Hemostasis abnormalities in cirrhosis. <i>Current Opinion in Hematology</i> , <b>2015</b> , 22, 406-12	3.3	41

118	How the direct oral anticoagulant apixaban affects thrombin generation parameters. <i>Thrombosis Research</i> , <b>2015</b> , 135, 1186-90	8.2	31
117	How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2015</b> , 53, 265-73	5.9	13
116	Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 277-8	13.4	3
115	Laboratory tests during direct oral anticoagulant treatment. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 903-5	3.7	2
114	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 148-54	13.4	113
113	Statins decrease thrombin generation in patients with hypercholesterolemia. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 449-51	3.9	12
112	Comments on: Laboratory tests for the management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants: proposals of the Working Group on Perioperative Haemostasis (GIHP). <i>Archives of Cardiovascular Diseases</i> , <b>2014</b> , 107, 345-6	2.7	3
111	Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. <i>Thrombosis Research</i> , <b>2014</b> , 133, 1130-4	8.2	7
110	Reply to: is platelet transfusion necessary in cirrhotic patients with splenomegaly?. <i>Liver International</i> , <b>2014</b> , 34, 478-9	7.9	
109	D-dimer testing for suspected venous thromboembolism in the emergency department. Consensus document of AcEMC, CISMEL, SIBioC, and SIMeL. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2014</b> , 52, 621-8	5.9	30
108	Should We Be Concerned About Coagulation in the Treatment of Acute Variceal Hemorrhage? <b>2014</b> , 203-210		
107	Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants. <i>Thrombosis Journal</i> , <b>2013</b> , 11, 9	5.6	7
106	Documento di consenso FCSA, SIMeL, SIBioC e CISMEL sul monitoraggio di laboratorio dei nuovi farmaci anticoagulanti orali. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , <b>2013</b> , 9, 131-133	1.1	1
105	Global coagulation in myeloproliferative neoplasms. <i>Annals of Hematology</i> , <b>2013</b> , 92, 1633-9	3	21
104	Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 265-70	13.4	113
103	The laboratory and the new oral anticoagulants. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 353-62	5.5	52
102	Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia. <i>Hepatology</i> , <b>2013</b> , 58, 1177-80	11.2	8
101	Anticoagulant treatment with rivaroxaban in severe protein S deficiency. <i>Pediatrics</i> , <b>2013</b> , 132, e1435-9	7.4	30

100	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. <i>Liver International</i> , <b>2013</b> , 33, 362-7	7.9	84
99	The laboratory and the direct oral anticoagulants. <i>Blood</i> , <b>2013</b> , 121, 4032-5	2.2	86
98	Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 46-52	7	16
97	Liver disease, coagulopathies and transfusion therapy. <i>Blood Transfusion</i> , <b>2013</b> , 11, 32-6	3.6	22
96	Unbalanced oxidative status in idiopathic sudden sensorineural hearing loss. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2012</b> , 269, 449-53	3.5	56
95	Circulating microparticles and risk of venous thromboembolism. <i>Thrombosis Research</i> , <b>2012</b> , 129, 591-7	8.2	75
94	Laboratory tests and the new oral anticoagulants. <i>Thrombosis Research</i> , <b>2012</b> , 130 Suppl 1, S95-7	8.2	11
93	Management of special conditions in patients on vitamin K antagonists. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 407-13	3.7	1
92	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 139-44	3.7	73
91	Problems and solutions for testing hemostasis assays while patients are on anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 586-92	5.3	11
90	To mix or not to mix in lupus anticoagulant testing? That is the question. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 385-9	5.3	27
89	Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1). <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2012</b> , 50, 2137-40	5.9	19
88	Hemostatic defects in liver and renal dysfunction. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 168-173	3.1	37
87	The coagulopathy of chronic liver disease. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 147-56	59.2	935
86	Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. <i>Thrombosis Research</i> , <b>2011</b> , 127, 589-94	8.2	8
85	Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 735-6	7	15
84	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 868-76	7	135
83	Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 165-72	5.1	102

82	The validity of the INR system for patients with liver disease. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 209-10	5.1	3
81	D-dimer testing in laboratory practice. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 1256-62	5.5	125
80	Haemostasis Abnormalities in Chronic Liver Failure <b>2011</b> , 289-303		7
79	Pro-coagulant imbalance in patients with chronic liver disease. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 586-7	13.4	8
78	The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? No. <i>European Journal of Internal Medicine</i> , <b>2010</b> , 21, 65-9	3.9	26
77	Increased thrombin generation in inflammatory bowel diseases. <i>Thrombosis Research</i> , <b>2010</b> , 125, 278-82	8.2	52
76	Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. <i>Internal and Emergency Medicine</i> , <b>2010</b> , 5, 7-12	3.7	43
75	Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2010</b> , 30, 215-9	5.1	14
74	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. <i>Hepatology</i> , <b>2010</b> , 52, 249-55	11.2	103
73	Laboratory monitoring of anticoagulation: where do we stand?. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2009</b> , 35, 34-41	5.3	22
72	Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. <i>British Journal of Haematology</i> , <b>2009</b> , 147, 77-82	4.5	91
71	The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. <i>Thrombosis Research</i> , <b>2009</b> , 124, 132-6	8.2	127
70	A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. <i>Thrombosis Research</i> , <b>2009</b> , 124, 137-43	8.2	25
69	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 288-95	13.4	25
68	An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. <i>Gastroenterology</i> , <b>2009</b> , 137, 2105-11	13.3	385
67	Tests of coagulation in liver disease. <i>Clinics in Liver Disease</i> , <b>2009</b> , 13, 55-61	4.6	35
66	Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. <i>Haematologica</i> , <b>2009</b> , 94, 1520-7	6.6	66
65	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1534-41	15.4	51



64	Reply to: Endogenous heparinoids contribute to coagulopathy in patients with liver disease. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 372-373	13.4	5
63	Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2008</b> , 34, 373-9	5.3	28
62	The history of phenotypic testing in thrombosis and hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2008</b> , 34, 585-92	5.3	12
61	Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. <i>Haematologica</i> , <b>2008</b> , 93, 900-7 <sup>6</sup>	6.6	27
60	Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests. <i>Haematologica</i> , <b>2008</b> , 93, 1256-9	6.6	53
59	How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation. <i>Hepatology</i> , <b>2008</b> , 47, 1423-4; author reply 1424	11.2	11
58	Hemostasis abnormalities in liver cirrhosis: myth or reality? <b>2008</b> , 118, 445-8		2
57	The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. <i>Hepatology</i> , <b>2007</b> , 46, 520-7	11.2	158
56	Laboratory testing for lupus anticoagulants: a review of issues affecting results. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1629-35	5.5	52
55	A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, e309-10	9.4	33
54	Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay. <i>Blood Coagulation and Fibrinolysis</i> , <b>2007</b> , 18, 543-6	1	2
53	Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. <i>Thrombosis Research</i> , <b>2007</b> , 120, 127-33	8.2	67
52	The endogenous thrombin potential and the risk of venous thromboembolism. <i>Thrombosis Research</i> , <b>2007</b> , 121, 353-9	8.2	56
51	Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. <i>Journal of Hepatology</i> , <b>2007</b> , 46, 727-33	13.4	147
50	Thrombin generation in patients with cirrhosis: the role of platelets. <i>Hepatology</i> , <b>2006</b> , 44, 440-5	11.2	289
49	A National Field Study of Quality Assessment of CoaguChek Point-of-Care Testing Prothrombin Time Monitors. <i>American Journal of Clinical Pathology</i> , <b>2006</b> , 126, 756-761	1.9	28
48	D-dimer testing to determine the duration of anticoagulation therapy. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 1780-9	59.2	493
47	Thrombin Generation in Severe Hemophiliacs with Different Clinical Phenotype.. <i>Blood</i> , <b>2006</b> , 108, 1000-1000	10.0	1

46	Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1883-5	5.5	36
45	Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. <i>Hepatology</i> , <b>2005</b> , 41, 553-8	11.2	506
44	Issues concerning the laboratory investigation of inherited thrombophilia. <i>Molecular Diagnosis and Therapy</i> , <b>2005</b> , 9, 181-6		9
43	A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2005</b> , 31, 25-32	5.3	33
42	Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1310-1	5.5	12
41	Issues Concerning the Laboratory Investigation of Inherited Thrombophilia <b>2005</b> , 9, 181		2
40	European concerted action on anticoagulation. Quality assessment of the CoaguChek Mini and TAS PT-NC point-of-care whole-blood prothrombin time monitors. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 537-44	5.5	18
39	Standardization of the endogenous thrombin potential measurement: how to minimize the effect of residual platelets in stored plasma. <i>British Journal of Haematology</i> , <b>2004</b> , 124, 355-7	4.5	16
38	Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation. <i>Thrombosis Research</i> , <b>2004</b> , 113, 35-40	8.2	14
37	Prothrombin time international normalized ratio monitoring by self-testing. <i>Current Opinion in Hematology</i> , <b>2004</b> , 11, 141-5	3.3	7
36	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. <i>Blood</i> , <b>2004</b> , 104, 3631-4	2.2	143
35	Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 1608-14	5.5	61
34	International Sensitivity Index Calibration of the Near-Patient Testing Prothrombin Time Monitor, ProTime. <i>American Journal of Clinical Pathology</i> , <b>2003</b> , 119, 241-245	1.9	9
33	Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods. <i>BMJ, The</i> , <b>2003</b> , 327, 30	5.9	32
32	European Concerted Action on Anticoagulation. <i>American Journal of Clinical Pathology</i> , <b>2003</b> , 119, 232-240		7
31	Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home-made methods. <i>British Journal of Haematology</i> , <b>2003</b> , 120, 825-8	4.5	6
30	Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. <i>Haematologica</i> , <b>2003</b> , 88, 547-54	6.6	126
29	Levels of coagulation factors and venous thromboembolism. <i>Haematologica</i> , <b>2003</b> , 88, 705-11	6.6	27

28	Laboratory Diagnosis of Lupus Anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 87, 854-858	7	14
27	Laboratory diagnosis of thrombophilic states: where do we stand?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2002</b> , 32, 245-8		5
26	Laboratory Diagnosis of Lupus Anticoagulants for Patients on Oral Anticoagulant Treatment. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 583-586	7	59
25	Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations [A Cause for Concern. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 690-691	7	37
24	How to evaluate the influence of blood collection systems on the international sensitivity index. Protocol applied to two new evacuated tubes and eight coagulometer/thromboplastin combinations. <i>Thrombosis Research</i> , <b>2002</b> , 108, 85-9	8.2	20
23	European Concerted Action on Anticoagulation. Evaluation of a Method for International Sensitivity Index Calibration of Two Point-of-Care Prothrombin Time (PT) Monitoring Systems (CoaguChek Mini and TAS PT-NC) with Fresh Plasmas Based on Whole-Blood Equivalent PT. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 1673-1680	5.5	13
22	European Concerted Action on Anticoagulation. Use of Plasma Samples to Derive International Sensitivity Index for Whole-Blood Prothrombin Time Monitors. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 255-260	5.5	22
21	Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 583-6	7	13
20	Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations--a cause for concern. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 690-1	7	5
19	Near-patient testing devices to monitor oral anticoagulant therapy. <i>British Journal of Haematology</i> , <b>2001</b> , 113, 847-52	4.5	35
18	Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. <i>British Journal of Haematology</i> , <b>2001</b> , 115, 672-8	4.5	67
17	Multicenter Study of Homocysteine Measurement [Performance Characteristics of Different Methods, Influence of Standards on Interlaboratory Agreement of Results. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 85, 291-295	7	47
16	Laboratory Investigation of Thrombophilia. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1597-1606	5.5	98
15	Hyperprothrombinemia may result in acquired activated protein C resistance. <i>Blood</i> , <b>2000</b> , 96, 3295-3296.2		26
14	Alpha(2)-macroglobulin levels are high in adult patients with congenital antithrombin deficiency. <i>Thrombosis Research</i> , <b>2000</b> , 98, 117-22	8.2	5
13	Calibration of Local Systems with Lyophilized Calibrant Plasmas Improves the Interlaboratory Variability of the INR in the Italian External Quality Assessment Scheme. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 82, 1621-1626	7	22
12	Standardization of the APC Resistance Test. Effects of Normalization of Results by Means of Pooled Normal Plasma. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 79, 564-566	7	14
11	Assessment of the Influence of Citrate Concentration on the International Normalized Ratio (INR) Determined with Twelve Reagent-instrument Combinations. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 80, 258-262	7	34

10	International Collaborative Study for the Calibration of a Proposed Reference Preparation for Thromboplastin, Human Recombinant, Plain. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 79, 439-443	7	52
9	Screening for the FV: Q506 Mutation [Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 77, 436-439	7	41
8	Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 855-858	7	24
7	Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio?. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 0921-0924	7	55
6	Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. <i>Thrombosis Research</i> , <b>1992</b> , 67, 355-65	8.2	52
5	Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 042-045	7	14
4	Laboratory Screening of Inherited Thrombotic Syndromes. <i>Thrombosis and Haemostasis</i> , <b>1987</b> , 57, 247-251		51
3	Factor VIII activity as measured by an amidolytic assay compared with a one-stage clotting assay. <i>American Journal of Clinical Pathology</i> , <b>1986</b> , 86, 341-4	1.9	9
2	The Coagulopathy of Chronic Liver Disease. Is the Long and Widely Held Belief Being Dispelled?165-170		
1	Monitoring Oral Anticoagulant Therapy with Vitamin K Antagonists253-263		